WSFS
MDGL icon

Wilmington Savings Fund Society’s Madrigal Pharmaceuticals MDGL Stock Holding History

Wilmington Savings Fund Society’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2
Closed -$617 – 2119
2024
Q4 		$617 Sell
2
-2
-50% -$563 ﹤0.01% 2030
2024
Q3 		$849 Buy
+4
New +$1.02K ﹤0.01% 1989

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wilmington Savings Fund Society's MDGL Position: Q1 2025 in Review

Wilmington Savings Fund Society sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2025, closing a stake of 2 shares — an estimated $617 sold.

Wilmington Savings Fund Society first reported a position in MDGL in Q3 2024 and held it in 2 quarters. The position peaked at $849 in Q3 2024. 321 funds tracked by Wall St. Rank hold MDGL as of Q1 2025.

  • Wilmington Savings Fund Society reported no remaining Madrigal Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Wilmington Savings Fund Society sold 2 Madrigal Pharmaceuticals shares in Q1 2025, an estimated $617.
  • Wilmington Savings Fund Society first reported a position in Madrigal Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Wilmington Savings Fund Society's Madrigal Pharmaceuticals position peaked at $849 in Q3 2024.
  • 321 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2025.

Based on Wilmington Savings Fund Society's 13F filing for Q1 2025, filed 8 May 2025.